Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC - Summary - DentalSpire

Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC

  • By

  • Dongmei Ji

  • Wenmin Fu

  • Yonghong Liu

  • Weina Shen

  • Muyu Kuang

  • Zhouyu Ning

  • Youzhou Sang

  • Guangliang Chen

  • Jian Zhang

  • Zijie Zhou

  • Dashuang Xu

  • Xu Jin

  • Junlong Wu

  • Xusha Zhou

  • Jing Zhao

  • Lei Wang

  • Yukun Liu

  • Xi Zhang

  • Runbin Yan

  • Xiaoqing Chen

  • Grace Zhou

  • Jiaxin Niu

  • Xichun Hu

  • February 20, 2026

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of T3011, an oncolytic virus, in patients with advanced or metastatic solid tumors, specifically including recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Key Findings:
  • T3011 demonstrated a favorable safety profile with manageable adverse events, with specific rates of adverse events to be detailed.
  • The therapy induced significant intratumoral accumulation of IL-12 and PD-1 antibody, with quantifiable metrics.
  • Preliminary efficacy data showed potential anti-tumor activity in advanced solid tumors, warranting further investigation.
Interpretation:

T3011's localized delivery of IL-12 and PD-1 antibody may enhance anti-tumor immunity while minimizing systemic toxicity, offering a promising therapeutic strategy for HNSCC and other solid tumors, particularly when compared to traditional systemic therapies.

Limitations:
  • The study's open-label design may introduce bias, potentially affecting the perceived efficacy.
  • Limited sample size may affect the generalizability of the findings.
  • Short follow-up period may not capture long-term efficacy and safety.
Conclusion:

T3011 represents a novel therapeutic approach for advanced solid tumors, particularly HNSCC, with the potential to improve patient outcomes through localized immune modulation, necessitating further studies to validate these findings.

Original Source(s)

Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC

  • by Dongmei Ji, Wenmin Fu, Yonghong Liu, Weina Shen, Muyu Kuang, Zhouyu Ning, Youzhou Sang, Guangliang Chen, Jian Zhang, Zijie Zhou, Dashuang Xu, Xu Jin, Junlong Wu, Xusha Zhou, Jing Zhao, Lei Wang, Yukun Liu, Xi Zhang, Runbin Yan, Xiaoqing Chen, Grace Zhou, Jiaxin Niu, Xichun Hu

  • February 20, 2026

Related Content

Ergonomic Risk in Head and Neck Surgery

Study suggests intraoperative pain and risk rise with case complexity and duration.

Poor Diet Quality Linked to Oral Cancer

Large prospective cohort data showed stronger associations among women without substantial tobacco or alcohol exposure.

When Dental Decay Triggers Deadly Infection

Case underscores gaps in preventive dental care and the consequences of separating oral and systemic health.